Aficamten

Aficamten, sold under the brand name Myqorzo, is a medication used for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Aficamten, sold under the brand name Myqorzo, is a medication used for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. It is a cardiac myosin inhibitor developed by Cytokinetics. Aficamten binds directly to the motor domain of cardiac myosin and prevents it from entering the force-producing state.

This lowers cardiac contractility, leading to reduced left ventricular outflow tract obstruction in people with hypertrophic cardiomyopathy. Aficamten was approved for medical use in the United States in December 2025, and in the European Union in February 2026.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1344604113 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

5 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.